BRCA2 and ovarian serous adenocarcinoma: In a separate dataset (dataset B—Supplementary Table 1) of 292 patients with high-grade serous ovarian cancer (from OV_tcga_pan_can_atlas_2018) (with 18 BRCA1-mutated OCs, 12 BRCA2-mutated OCs and 262 tumours with no mutations in either BRCA1 or BRCA2), XIAP protein expression by RPPA was also significantly higher in BRCA1-mutated versus BRCA1/2-wild-type OCs (Fig. 1e), thereby definitively confirming an association between increased XIAP protein expression and BRCA1 mutation status in OC.